* Aquila Biopharmaceuticals Inc., of Worcester, Mass., said it received a scheduled license fee payment of "several million dollars" from SmithKline Beecham plc, of London. The payment was the last in a series due from a 1992 agreement, under which SmithKline is developing new-generation vaccines containing Aquila's proprietary Stimulon adjuvants. SmithKline has a broad ongoing program using Aquila's adjuvant QS-21 in formulating vaccines for herpes, hepatitis, HIV, malaria and human papillomavirus genital warts.
* Dyax Corp., of Cambridge, Mass., signed a collaborative agreement with Genetics Institute Inc. (GI), also of Cambridge, for the discovery and development of affinity ligands to streamline the purification of one of GI's lead biotherapeutic candidates. Dyax will use its Phase Display technology. GI is a wholly owned subsidiary of American Home Products Corp., of Madison, N.J.
* Neurobiological Technologies Inc., of Richmond, Calif., said a trial of Memantine in patients with neuropathic pain due to diabetes or post-herpetic neuralgia showed favorable results. On average, diabetics treated with Memantine had an 18 percent reduction in daytime pain and a 30 percent reduction in nighttime pain, with 29 percent greater pain relief compared to placebo. No significant differences from placebo were observed in the post-herpetic neuralgia patients dosing with Memantine, an orally available N-methyl D-aspartate receptor antagonist.